Jehangir Ali Shah, MBBS Credit: ACC Rivaroxaban achieved comparable efficacy and safety to warfarin in resolving left ventricular blood clots in patients hospitalized with myocardial infarction (MI) without displaying evidence of excess harm, including mortality and bleeding risks.1 The open-label, non-inferiority, randomized controlled RIVAWAR trial, presented at the American College of Cardiology (ACC) 2025 Annual … Read more
New data from an analysis of the FIGHT trial presented at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions details significant disparities in heart failure outcomes among patients with heart failure with reduced left ventricular ejection fraction (LVEF) following hospitalization. A phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart … Read more
Carolyn Hendrickson, MD Credit: ACC Pulse oximeter estimates of blood oxygen saturation levels and traditional measurements of oxygen saturation in arterial blood significantly diverged by skin pigment in critically ill adults in the EquiOx study, according to new research presented at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions.1 These data from a … Read more
Stefan D. Anker, MD Credit: ACC Intravenous iron supplementation was safe but did not significantly lower the time to first heart failure (HF) hospitalization or cardiovascular death among patients with reduced ejection fraction (HFrEF) and iron deficiency in new data at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions.1 The FAIR-HF2 trial, enrolling … Read more
Sergio Raposeiras-Roubin, MD Credit: ACC Daily dapagliflozin significantly lowered the incidence of mortality or worsening disease among patients with heart failure (HF) at 1 year after transcatheter aortic valve implantation (TAVI), according to new data presented at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions.1 DapaTAVI was the first trial to evaluate sodium-glucose … Read more
John H. Alexander, MD, MHS Credit: Duke University Oral anti-coagulant (OAC)-naive individuals with atrial fibrillation (AF) showed a significantly smaller increase in stroke or systemic embolism with the use of asundexian versus apixaban than individuals with prior OAC exposure, according to new findings.1 This secondary analysis of the Oral Factor 11a Inhibitor Asundexian as Novel … Read more
A new investigation identified a link between an elevated non-high-density lipoprotein cholesterol (non-HDL-C) to high-density lipoprotein cholesterol (HDL-C) ratio (NHHR) and the likelihood of ischemic heart disease (IHD) among patients with type 2 diabetes (T2D).1 Across a median follow-up of nearly 13 years, this large, prospective cohort study, involving nearly 20,000 patients in the UK … Read more
Jyoti Tyagi, MPH Credit: Linkedin Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) seem to be a feasible alternative to erythropoietin-stimulating agents (ESA) for treating anemia in people with dialysis-dependent chronic kidney disease (DD-CKD), according to a new systematic review and meta-analysis.1 Specifically, daprodustat exhibited a substantial net benefit over ESAs in reducing the need for intravenous … Read more
Please enable Javascript Welcome to HCPLive’s 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check … Read more
Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals. Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it’s a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week’s top stories focused on … Read more